U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C6H8O6.C4H6N4O3
Molecular Weight 334.2396
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALLANTOIN ASCORBATE

SMILES

NC(=O)NC1NC(=O)NC1=O.[H][C@@]2(OC(=O)C(O)=C2O)[C@@H](O)CO

InChI

InChIKey=BMZVXYKKNCVBBF-RXSVEWSESA-N
InChI=1S/C6H8O6.C4H6N4O3/c7-1-2(8)5-3(9)4(10)6(11)12-5;5-3(10)6-1-2(9)8-4(11)7-1/h2,5,7-10H,1H2;1H,(H3,5,6,10)(H2,7,8,9,11)/t2-,5+;/m0./s1

HIDE SMILES / InChI
Molecular Formula C6H8O6
Molecular Weight 176.1241
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C4H6N4O3
Molecular Weight 158.1154
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: http://tri-k.com/acloxa

Aldioxa is the generic name for the metal complex, dihydroxyaluminum allantoinate, which is hydrolyzed to allantoin and aluminium hydrate at the gastric mucosa. Aldioxa was approved in Japan to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. It was discovered, that aldioxa ameliorates delayed gastric emptying through its antagonistic activity on the α-2 adrenergic receptor. The most commonly reported adverse reactions include constipation.

Approval Year

1961
146
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Not Provided
504
BODYGLIDE FOR HER

Approved Use

helps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns.

Launch Date

1.25902075E12
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Approved
8429
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Approved
8429
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Approved
8429
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.43 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9131540/
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
30 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9131540/
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.69 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9131540/
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:15676
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:15676
ChemicalBook
CB3215461
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3215461
MolPort
MolPort-001-779-876
https://www.molport.com/shop/molecule-link/MolPort-001-779-876
eMolecules
476195
https://www.emolecules.com/cgi-bin/more?vid=476195
PubMed

PubMed

TitleDatePubMed
[Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity].
1962 Jul-Aug
[Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions].
1994 Mar

Sample Use Guides

In Vivo Use Guide
Sources: file:///C:/Users/Mark/Desktop/info_20ALCLOXA.pdf
Antiperspirants, deodorants: Creams, spray, lossions: 0.25-0.5% Baby products: creams; powders: 0.2-0.5%
Route of Administration: Topical
In Vitro Use Guide
Sources: file:///C:/Users/Mark/Desktop/info_20ALCLOXA.pdf
In vitro Alcloxa inhibited formation and bacterial decomposition of pulverized human epidermal scales. The scales were obtained from patient with exfoliative dermatitis, characterized by a great deal of exudation. The scales were were pulverized in a Wiley mill, defatted with ether and suspended in a 0,2% Alcloxa solution.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:32:44 UTC 2023
Edited
by admin
on Fri Dec 15 15:32:44 UTC 2023
Record UNII
76WX3J5GER
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALLANTOIN ASCORBATE
INCI  
INCI  
Official Name English
UREA, (2,5-DIOXO-4-IMIDAZOLIDINYL)-, COMPD. WITH L-ASCORBIC ACID (1:1)
Common Name English
ALLANTOIN-ASCORBIC ACID COMPOUND
Common Name English
ALLANTOIN ASCORBATE [INCI]
Common Name English
L-ASCORBIC ACID, COMPD. WITH N-(2,5-DIOXO-4-IMIDAZOLIDINYL)UREA (1:1)
Common Name English
Code System Code Type Description
PUBCHEM
67732897
Created by admin on Fri Dec 15 15:32:44 UTC 2023 , Edited by admin on Fri Dec 15 15:32:44 UTC 2023
PRIMARY
CAS
127941-88-2
Created by admin on Fri Dec 15 15:32:44 UTC 2023 , Edited by admin on Fri Dec 15 15:32:44 UTC 2023
NON-SPECIFIC STOICHIOMETRY
DAILYMED
76WX3J5GER
Created by admin on Fri Dec 15 15:32:44 UTC 2023 , Edited by admin on Fri Dec 15 15:32:44 UTC 2023
PRIMARY
FDA UNII
76WX3J5GER
Created by admin on Fri Dec 15 15:32:44 UTC 2023 , Edited by admin on Fri Dec 15 15:32:44 UTC 2023
PRIMARY
EPA CompTox
DTXSID90972924
Created by admin on Fri Dec 15 15:32:44 UTC 2023 , Edited by admin on Fri Dec 15 15:32:44 UTC 2023
PRIMARY
RXCUI
2559842
Created by admin on Fri Dec 15 15:32:44 UTC 2023 , Edited by admin on Fri Dec 15 15:32:44 UTC 2023
PRIMARY
CAS
57448-83-6
Created by admin on Fri Dec 15 15:32:44 UTC 2023 , Edited by admin on Fri Dec 15 15:32:44 UTC 2023
PRIMARY
ECHA (EC/EINECS)
260-739-1
Created by admin on Fri Dec 15 15:32:44 UTC 2023 , Edited by admin on Fri Dec 15 15:32:44 UTC 2023
PRIMARY
Related Record Type Details
Structure of ASCORBIC ACID
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966